Matinas BioPharma Holdings Inc
$ 0.72
-4.19%
16 Jun - close price
- Market Cap 4,815,500 USD
- Current Price $ 0.72
- High / Low $ 0.80 / 0.72
- Stock P/E N/A
- Book Value 0.47
- EPS -1.97
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.48 %
- ROE -2.28 %
- 52 Week High 3.09
- 52 Week Low 0.48
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of several candidate products. The company is headquartered in Bedminster, New Jersey.
Analyst Target Price
$30.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-31 | 2025-11-10 | 2025-08-14 | 2025-04-15 | 2025-03-26 | 2024-11-13 | 2024-08-14 | 2024-05-09 | 2024-03-27 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | -0.2985 | -0.4 | -1.03 | -0.81 | -0.8056 | -0.85 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 |
| Estimated EPS | None | None | None | None | -0.78 | -0.78 | -1.05 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 |
| Surprise | 0 | 0 | 0 | 0 | -0.03 | -0.0256 | 0.2 | 0 | 0 | 0.01 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | -3.8462% | -3.2821% | 19.0476% | 0% | 0% | 33.3333% | 0% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MTNB
2026-06-16 20:05:49
Matinas BioPharma (NYSEAM: MTNB) has filed a shelf registration to offer up to $150 million in various securities, including common stock, preferred stock, warrants, debt securities, subscription rights, or units. The proceeds from these potential offerings are intended for working capital and general corporate purposes, allowing the company to access capital markets opportunistically. As of June 16, 2026, Matinas BioPharma had 6,406,191 shares of common stock issued and outstanding, with a public float of approximately $5.58 million.
2026-05-12 07:39:44
This page provides an overview of Matinas BioPharma Holdings Inc (MTNB) stock on TradingKey. It includes current stock quotes, market capitalization, and a section for financial discussions. Users can also find links to various analytical tools and educational resources offered by TradingKey.
2026-05-08 21:09:38
Matinas BioPharma Holdings, Inc. (MTNB) filed its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The company reported a net loss of $1.921 million for the quarter, compared to $1.656 million in the same period last year, and continues to experience net losses and negative cash flows. Matinas BioPharma acknowledged substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months, with its strategy relying on securing partners for MAT2203, controlling expenses, and additional financing. The company also disclosed that it received a notice of non-compliance with NYSE American's continued listing standards related to stockholders' equity.
2026-04-19 09:08:53
This article provides financial information for Matinas BioPharma Holdings, Inc. (FWB:6LJ0), specifically focusing on its operating cash flow per share. It presents a table showing historical values and changes without specific numerical data in this excerpt. The data is sourced from ICE Data Services and FactSet for reference.
2026-04-18 14:40:19
This article focuses on the net current asset value per share of Matinas BioPharma Holdings, Inc. (FWB:6LJ0). It provides a financial overview of the company's stock on the Frankfurt Stock Exchange. The content is primarily a data placeholder from TradingView, indicating where specific financial data for Matinas BioPharma Holdings, Inc. would be displayed.
2026-04-04 03:09:45
Matinas BioPharma received a non-compliance notice from NYSE American on April 2, 2026, due to insufficient shareholder equity of $4.83 million as of December 31, 2025. The company must submit a compliance plan by May 2, 2026, and has 18 months to regain compliance. Continuous losses over the past five fiscal years have removed any exemption eligibility, increasing financial and operational pressures.
